EyePoint Pharmaceuticals, Inc. (EYPT)
USD 7.3
(2.38%)
USD 7.3
(2.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -69 Million USD | 2.09% |
| 2022 | -96.61 Million USD | -42.33% |
| 2021 | -50.14 Million USD | -51.05% |
| 2020 | -35.48 Million USD | 21.59% |
| 2019 | -48.01 Million USD | -69.44% |
| 2018 | -36.99 Million USD | -40.9% |
| 2017 | -18.57 Million USD | 14.69% |
| 2016 | -17.67 Million USD | -439.11% |
| 2015 | -20.86 Million USD | 150.78% |
| 2014 | 7.3 Million USD | -5.24% |
| 2013 | -12.65 Million USD | -380.72% |
| 2012 | -11.03 Million USD | 138.45% |
| 2011 | -22.77 Million USD | -217.99% |
| 2010 | -5.49 Million USD | 1010.52% |
| 2009 | 9.09 Million USD | -103.85% |
| 2008 | -24 Thousand USD | -57.25% |
| 2007 | -75.64 Million USD | 385.3% |
| 2006 | -22.04 Million USD | -183.4% |
| 2005 | -18.97 Million USD | -10.95% |
| 2004 | -9.43 Million USD | -107.14% |
| 2003 | -5.99 Million USD | -164.67% |
| 2002 | -3.38 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -34.18 Million USD | -5.12% |
| 2024 Q1 | -33.01 Million USD | -108.44% |
| 2023 FY | - USD | 2.09% |
| 2023 Q3 | -12.61 Million USD | 40.33% |
| 2023 Q4 | -16.24 Million USD | -28.78% |
| 2023 Q1 | -20.35 Million USD | 6.5% |
| 2023 Q2 | -21.13 Million USD | -3.86% |
| 2022 Q2 | -18.15 Million USD | -3.55% |
| 2022 Q3 | -17.14 Million USD | 5.55% |
| 2022 Q4 | -21.76 Million USD | -26.97% |
| 2022 Q1 | -17.52 Million USD | -0.56% |
| 2022 FY | - USD | -42.33% |
| 2021 Q4 | -17.42 Million USD | -18.63% |
| 2021 Q3 | -14.69 Million USD | -46.71% |
| 2021 FY | - USD | -51.05% |
| 2021 Q1 | -10.24 Million USD | 15.46% |
| 2021 Q2 | -10.01 Million USD | 2.28% |
| 2020 Q3 | -1.34 Million USD | 87.19% |
| 2020 Q2 | -10.47 Million USD | 2.79% |
| 2020 FY | - USD | 21.59% |
| 2020 Q4 | -12.12 Million USD | -803.28% |
| 2020 Q1 | -10.77 Million USD | -34.55% |
| 2019 Q4 | -8 Million USD | 39.48% |
| 2019 Q1 | -13.79 Million USD | -28.1% |
| 2019 Q2 | -9.25 Million USD | 32.94% |
| 2019 Q3 | -13.23 Million USD | -43.04% |
| 2019 FY | - USD | -69.44% |
| 2018 Q2 | -9.75 Million USD | -322.29% |
| 2018 Q4 | -10.76 Million USD | 19.8% |
| 2018 FY | - USD | -40.9% |
| 2018 Q1 | -2.31 Million USD | 60.23% |
| 2018 Q3 | -13.42 Million USD | -37.62% |
| 2017 Q3 | -5.78 Million USD | 5.72% |
| 2017 FY | - USD | 14.69% |
| 2017 Q1 | -5.16 Million USD | -5389.36% |
| 2017 Q2 | -6.13 Million USD | -18.91% |
| 2017 Q4 | -5.8 Million USD | -0.4% |
| 2016 FY | - USD | -439.11% |
| 2016 Q4 | -94 Thousand USD | 98.69% |
| 2016 Q2 | -6.45 Million USD | -32.3% |
| 2016 Q3 | -7.18 Million USD | -11.31% |
| 2016 Q1 | -4.88 Million USD | 6.83% |
| 2015 Q1 | -4.84 Million USD | -17.59% |
| 2015 Q3 | -4.76 Million USD | 8.4% |
| 2015 FY | - USD | 150.78% |
| 2015 Q2 | -5.2 Million USD | -7.44% |
| 2015 Q4 | -5.23 Million USD | -9.97% |
| 2014 Q4 | -4.11 Million USD | -119.58% |
| 2014 Q3 | 21.02 Million USD | 656.23% |
| 2014 Q2 | -3.77 Million USD | -89.8% |
| 2014 FY | - USD | -5.24% |
| 2014 Q1 | -1.99 Million USD | 44.88% |
| 2013 Q1 | -2.56 Million USD | 3.06% |
| 2013 Q4 | -3.61 Million USD | 2.82% |
| 2013 FY | - USD | -380.72% |
| 2013 Q3 | -3.71 Million USD | 6.58% |
| 2013 Q2 | -3.97 Million USD | -55.25% |
| 2012 Q3 | -2.58 Million USD | -12.08% |
| 2012 Q4 | -2.64 Million USD | -2.12% |
| 2012 Q2 | -2.31 Million USD | 7.3% |
| 2012 Q1 | -2.49 Million USD | -120.96% |
| 2012 FY | - USD | 138.45% |
| 2011 Q2 | -316 Thousand USD | 87.98% |
| 2011 Q3 | -2.57 Million USD | -713.61% |
| 2011 FY | - USD | -217.99% |
| 2011 Q4 | 11.88 Million USD | 562.43% |
| 2011 Q1 | -2.62 Million USD | 4.09% |
| 2010 Q4 | -2.74 Million USD | 6.9% |
| 2010 Q3 | -2.94 Million USD | -124.95% |
| 2010 Q2 | 11.8 Million USD | 481.51% |
| 2010 FY | - USD | 1010.52% |
| 2010 Q1 | -3.09 Million USD | -1510.94% |
| 2009 FY | - USD | -103.85% |
| 2009 Q1 | 36 Thousand USD | 104.54% |
| 2009 Q2 | 776 Thousand USD | 2055.56% |
| 2009 Q3 | 1.4 Million USD | 80.8% |
| 2009 Q4 | -192 Thousand USD | -113.68% |
| 2008 FY | - USD | -57.25% |
| 2008 Q1 | -6.76 Million USD | 25.85% |
| 2008 Q4 | -793 Thousand USD | 71.22% |
| 2008 Q3 | -2.75 Million USD | -105.12% |
| 2008 Q2 | 53.85 Million USD | 896.61% |
| 2007 Q3 | -8.23 Million USD | 77.93% |
| 2007 Q4 | -9.11 Million USD | -10.7% |
| 2007 FY | - USD | 385.3% |
| 2007 Q1 | 65 Thousand USD | -99.78% |
| 2007 Q2 | -37.32 Million USD | -57518.46% |
| 2006 Q3 | 790.44 Thousand USD | 102.75% |
| 2006 Q4 | 29.14 Million USD | 3587.8% |
| 2006 FY | - USD | -183.4% |
| 2006 Q1 | 351.9 Thousand USD | -47.53% |
| 2006 Q2 | -28.73 Million USD | -8264.8% |
| 2005 Q1 | 160.36 Thousand USD | -0.9% |
| 2005 Q3 | 375.12 Thousand USD | 103.49% |
| 2005 Q4 | 670.7 Thousand USD | 78.8% |
| 2005 Q2 | -10.73 Million USD | -6793.91% |
| 2005 FY | - USD | -10.95% |
| 2004 FY | - USD | -107.14% |
| 2004 Q4 | 161.81 Thousand USD | 7.34% |
| 2004 Q1 | 72.86 Thousand USD | 1.49% |
| 2004 Q2 | -6.45 Million USD | -8959.25% |
| 2004 Q3 | 150.74 Thousand USD | 102.34% |
| 2003 Q1 | 16.72 Thousand USD | 7.78% |
| 2003 Q3 | 64.89 Thousand USD | 101.78% |
| 2003 Q4 | 71.79 Thousand USD | 10.63% |
| 2003 FY | - USD | -164.67% |
| 2003 Q2 | -3.64 Million USD | -21905.01% |
| 2002 Q3 | 15.02 Thousand USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | 15.52 Thousand USD | 3.31% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 21.076% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 47.094% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -23611.684% |
| Autolus Therapeutics plc | -156.77 Million USD | 55.986% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -640.016% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | -144.52% |
| Shattuck Labs, Inc. | -87.61 Million USD | 21.245% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 43.555% |
| CervoMed Inc. | -2.17 Million USD | -3077.026% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 70.839% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -55.279% |
| Aptose Biosciences Inc. | -52.26 Million USD | -32.014% |
| Precision BioSciences, Inc. | -32.04 Million USD | -115.345% |
| Dyadic International, Inc. | -8.22 Million USD | -738.435% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 13.854% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -584.127% |
| Nektar Therapeutics | -243.1 Million USD | 71.617% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -1501.323% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -135.836% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 14.8% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 63.544% |
| GRI Bio, Inc. | -10.89 Million USD | -533.153% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -1428.019% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 43.675% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -548.933% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -2407.686% |
| IGM Biosciences, Inc. | -253.35 Million USD | 72.765% |
| INmune Bio, Inc. | - USD | Infinity% |
| Opthea Limited | -200.01 Million USD | 65.503% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | -21.384% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 26.194% |
| Verastem, Inc. | -83.16 Million USD | 17.032% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -36.441% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 56.391% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 39.52% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 167.83% |
| NextCure, Inc. | -59.03 Million USD | -16.874% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | -246.523% |
| Organovo Holdings, Inc. | -14.8 Million USD | -366.034% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 2151674.68% |
| Arvinas, Inc. | -394.8 Million USD | 82.523% |
| Ovid Therapeutics Inc. | -58.71 Million USD | -17.522% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | -220.354% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | -5.705% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 58.45% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | -185.529% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 56.105% |
| Senti Biosciences, Inc. | -61.33 Million USD | -12.497% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -358.325% |
| Apollomics, Inc. | -171.74 Million USD | 59.824% |
| PureTech Health plc | -11.62 Million USD | -493.455% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 3187.293% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 7.771% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 51.815% |
| Synaptogenix, Inc. | -8.3 Million USD | -730.586% |
| ChromaDex Corporation | -3.89 Million USD | -1671.983% |
| Beam Therapeutics Inc. | -156.47 Million USD | 55.902% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 16182.687% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | -904.674% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 51.205% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 86.066% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 28011.219% |
| Gritstone bio, Inc. | -126.86 Million USD | 45.61% |
| Mesoblast Limited | -61.33 Million USD | -12.506% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -2967.094% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -190.714% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 59.936% |
| MediWound Ltd. | -4.89 Million USD | -1310.198% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 58.288% |
| Fortress Biotech, Inc. | -133.64 Million USD | 48.369% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | -36.5% |
| Achilles Therapeutics plc | -70.44 Million USD | 2.046% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 19.235% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -32.318% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | -120.071% |
| Zai Lab Limited | -366.57 Million USD | 81.177% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -1121.689% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 69.367% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -530.607% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 47.596% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -876.807% |
| FibroGen, Inc. | -261.4 Million USD | 73.604% |
| Celcuity Inc. | -58.3 Million USD | -18.335% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -519.343% |
| ContextLogic Inc. | -324 Million USD | 78.703% |
| GH Research PLC | -41.15 Million USD | -67.669% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 10.786% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | -171.422% |
| ImmuCell Corporation | -2.5 Million USD | -2655.546% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 272.978% |
| Amarin Corporation plc | -50.9 Million USD | -35.558% |
| TG Therapeutics, Inc. | 26.1 Million USD | 364.372% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | -143.725% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -6.18% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 33.942% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -168.779% |
| Aptorum Group Limited | -9.59 Million USD | -618.836% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 86.639% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 40.688% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | -171.743% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 60.722% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -283.905% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 45.17% |
| Ardelyx, Inc. | -55.35 Million USD | -24.654% |
| Ainos, Inc. | -8.77 Million USD | -686.507% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | -5.749% |
| Prothena Corporation plc | -190.1 Million USD | 63.704% |
| HilleVax, Inc. | -132.46 Million USD | 47.91% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 46.176% |
| Celularity Inc. | -183.94 Million USD | 62.488% |
| Rallybio Corporation | -72.37 Million USD | 4.659% |
| Cue Biopharma, Inc. | -46.05 Million USD | -49.833% |
| Omeros Corporation | -163.61 Million USD | 57.826% |
| Humacyte, Inc. | -96.45 Million USD | 28.465% |
| Immunocore Holdings plc | -59.64 Million USD | -15.678% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | -256.189% |
| Blueprint Medicines Corporation | -474.61 Million USD | 85.462% |
| IO Biotech, Inc. | -91.22 Million USD | 24.364% |
| MEI Pharma, Inc. | 26.38 Million USD | 361.566% |
| GT Biopharma, Inc. | 5.97 Million USD | 1254.056% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 5.78% |
| Summit Therapeutics Inc. | 1 Million USD | 6993.207% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | -123.275% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 45.018% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 59.038% |
| Pulmatrix, Inc. | -12.64 Million USD | -445.635% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | -109.31% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 35.575% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 22.004% |
| Acelyrin, Inc. | -381.52 Million USD | 81.914% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 86.372% |
| Cytokinetics, Incorporated | -456.68 Million USD | 84.891% |
| Vor Biopharma Inc. | -114.37 Million USD | 39.669% |
| Evogene Ltd. | -23.2 Million USD | -197.367% |
| Replimune Group, Inc. | -230.19 Million USD | 70.025% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -6.92% |
| PDS Biotechnology Corporation | -40.08 Million USD | -72.137% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -44954.816% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 87.798% |
| AEON Biopharma, Inc. | -48.36 Million USD | -42.679% |
| BioLineRx Ltd. | -57.06 Million USD | -20.925% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -34058.911% |
| Atai Life Sciences N.V. | -36.31 Million USD | -90.028% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 15.141% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | -112.618% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 74.955% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -124.466% |
| MediciNova, Inc. | -9.87 Million USD | -598.393% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 45.212% |
| MiMedx Group, Inc. | 40.51 Million USD | 270.301% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -4409.277% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 69.332% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 79.112% |
| Mereo BioPharma Group plc | -26.05 Million USD | -164.818% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 69.992% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -129.812% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 70.446% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -1340.081% |
| Allakos Inc. | -189.91 Million USD | 63.667% |
| scPharmaceuticals Inc. | -46.06 Million USD | -49.804% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 36.4% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 163.699% |
| NLS Pharmaceutics AG | -11.79 Million USD | -484.97% |
| Precigen, Inc. | -89.22 Million USD | 22.667% |
| XOMA Corporation | -39.36 Million USD | -75.299% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 30.48% |
| Incyte Corporation | 919.42 Million USD | 107.505% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -597.903% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 41.351% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 17.675% |
| Seer, Inc. | -97.88 Million USD | 29.508% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -186.17% |
| CRISPR Therapeutics AG | -202.7 Million USD | 65.959% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 53.576% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -405.391% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -757.976% |
| Akari Therapeutics, Plc | -16.8 Million USD | -310.671% |
| Novavax, Inc. | -487.39 Million USD | 85.843% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -980.06% |
| UroGen Pharma Ltd. | -63.83 Million USD | -8.1% |
| Sutro Biopharma, Inc. | -67.91 Million USD | -1.599% |
| Entera Bio Ltd. | -8.8 Million USD | -683.746% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | -170.391% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 38.559% |
| Chimerix, Inc. | -92.97 Million USD | 25.785% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 16.091% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 56.617% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | -20.261% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 104.761% |
| AnaptysBio, Inc. | -143.16 Million USD | 51.803% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -383.21% |
| Portage Biotech Inc. | -18.19 Million USD | -279.147% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 34.023% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 12.519% |
| OKYO Pharma Limited | -15.74 Thousand USD | -438116.497% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -510.609% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -727.548% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -502.269% |
| AbCellera Biologics Inc. | -192.15 Million USD | 64.092% |
| Genprex, Inc. | -31.06 Million USD | -122.15% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 63.205% |
| NLS Pharmaceutics AG | -11.79 Million USD | -484.97% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 45825.097% |
| Daré Bioscience, Inc. | -30.7 Million USD | -124.748% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -863.029% |
| Bicycle Therapeutics plc | -183.4 Million USD | 62.377% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 83.975% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 23.621% |
| Erasca, Inc. | -121.31 Million USD | 43.12% |
| bluebird bio, Inc. | -167.16 Million USD | 58.722% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | -203.141% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 122.238% |
| DBV Technologies S.A. | -85.98 Million USD | 19.749% |
| Fortress Biotech, Inc. | -133.64 Million USD | 48.369% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 70.449% |
| CorMedix Inc. | -48.88 Million USD | -41.144% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 78.85% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | -106.676% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | -34.718% |
| Spruce Biosciences, Inc. | -47.36 Million USD | -45.676% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 50.371% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 70.646% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 66.482% |
| Onconetix, Inc. | -36.7 Million USD | -87.979% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -592.225% |
| Prime Medicine, Inc. | -193.75 Million USD | 64.388% |
| Adagene Inc. | -14.95 Million USD | -361.521% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 66.617% |
| GlycoMimetics, Inc. | -39.12 Million USD | -76.374% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 109.686% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 68.3% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 154.566% |
| SciSparc Ltd. | -5.28 Million USD | -1206.342% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -72373.952% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | -218.103% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 16.896% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 354.11% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 36665.345% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 69.661% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -485.137% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 73.28% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -570.89% |
| 2seventy bio, Inc. | -206.41 Million USD | 66.572% |
| ADMA Biologics, Inc. | 5.12 Million USD | 1447.676% |
| Clene Inc. | -43.24 Million USD | -59.573% |
| Capricor Therapeutics, Inc. | -23 Million USD | -199.887% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | -42.338% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 76.966% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | -87.863% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 392.712% |
| Absci Corporation | -95.45 Million USD | 27.715% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 101.483% |
| Surrozen, Inc. | -41.13 Million USD | -67.759% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 38.684% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 2.848% |
| Cingulate Inc. | -22.95 Million USD | -200.631% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -824.822% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -738.778% |
| Jaguar Health, Inc. | -33.13 Million USD | -108.267% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 32.528% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | -1.731% |
| Kronos Bio, Inc. | -121.83 Million USD | 43.363% |
| Innoviva, Inc. | 248.96 Million USD | 127.716% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 7.184% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -21395.639% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 35.958% |
| Soligenix, Inc. | -7.85 Million USD | -778.675% |
| AlloVir, Inc. | -190.14 Million USD | 63.712% |
| Century Therapeutics, Inc. | -121.2 Million USD | 43.072% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 37.128% |
| Kura Oncology, Inc. | -164.95 Million USD | 58.17% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -7104.572% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 18.493% |
| Eterna Therapeutics Inc. | -19.93 Million USD | -246.147% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 13143.667% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 33.52% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -80.947% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -350.078% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -338.29% |
| HCW Biologics Inc. | -23.57 Million USD | -192.674% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 43.49% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 74.059% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 64.421% |
| Lantern Pharma Inc. | -15.78 Million USD | -337.083% |
| Histogen Inc. | -10.5 Million USD | -556.965% |
| Surrozen, Inc. | -41.13 Million USD | -67.759% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| Kodiak Sciences Inc. | -259.02 Million USD | 73.361% |
| MoonLake Immunotherapeutics | -54.1 Million USD | -27.52% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | -40.079% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 38.72% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | -146.829% |
| Moderna, Inc. | -3.28 Billion USD | 97.898% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 70.001% |
| Turnstone Biologics Corp. | -56.23 Million USD | -22.703% |
| Immix Biopharma, Inc. | -16.13 Million USD | -327.631% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -349.84% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | -9.444% |
| Exelixis, Inc. | 196.6 Million USD | 135.097% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 49.667% |
| Wave Life Sciences Ltd. | -58.79 Million USD | -17.369% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -21196.605% |
| Alkermes plc | 495.04 Million USD | 113.938% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -6.18% |
| Arcellx, Inc. | -64.14 Million USD | -7.57% |
| ESSA Pharma Inc. | -26.45 Million USD | -160.821% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -1625.048% |
| Avid Bioservices, Inc. | -11.48 Million USD | -501.002% |
| Insmed Incorporated | -654.73 Million USD | 89.461% |
| Cardiff Oncology, Inc. | -45.01 Million USD | -53.288% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 44.118% |
| Moolec Science SA | -52.07 Million USD | -32.502% |
| RenovoRx, Inc. | -11.39 Million USD | -505.803% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | -33.707% |
| Geron Corporation | -174.78 Million USD | 60.522% |
| LAVA Therapeutics N.V. | -40.41 Million USD | -70.723% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | -10.939% |
| Royalty Pharma plc | 1.88 Billion USD | 103.656% |
| OmniAb, Inc. | -49.73 Million USD | -38.748% |
| Alector, Inc. | -142.89 Million USD | 51.711% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 42.303% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 58.453% |
| Humacyte, Inc. | -96.45 Million USD | 28.465% |
| Structure Therapeutics Inc. | -102.45 Million USD | 32.655% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 76.259% |
| 89bio, Inc. | -134.46 Million USD | 48.684% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 1802.887% |
| Aura Biosciences, Inc. | -83.69 Million USD | 17.558% |
| Immunic, Inc. | -99.11 Million USD | 30.381% |
| Veracyte, Inc. | -49.4 Million USD | -39.653% |
| Genelux Corporation | -24.16 Million USD | -185.541% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | -104.145% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -885.542% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | -268.657% |
| Immunovant, Inc. | -269.97 Million USD | 74.442% |
| Vericel Corporation | 2.86 Million USD | 2509.253% |
| Fortrea Holdings Inc. | 167.3 Million USD | 141.244% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 48.614% |
| XBiotech Inc. | -35.76 Million USD | -92.923% |
| Agenus Inc. | -145.92 Million USD | 52.714% |
| Acasti Pharma Inc. | -11.3 Million USD | -510.574% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -458.712% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | -210.072% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -350.078% |
| Theravance Biopharma, Inc. | -40.86 Million USD | -68.843% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | -23.17% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -334.515% |
| Gain Therapeutics, Inc. | -22.16 Million USD | -211.242% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | -139.787% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | -138.238% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 59.041% |
| United Therapeutics Corporation | 1.38 Billion USD | 104.976% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -1148.763% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -1346.036% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 2151674.68% |
| Silo Pharma, Inc. | -3.62 Million USD | -1802.839% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -1028.104% |
| Pharming Group N.V. | 9.87 Million USD | 798.603% |
| XOMA Corporation | -39.36 Million USD | -75.299% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -186.17% |
| Bionomics Limited | -9.83 Million USD | -601.444% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -99.39% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 12.093% |
| uniQure N.V. | -253.1 Million USD | 72.738% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 6.508% |
| Cassava Sciences, Inc. | -95.68 Million USD | 27.889% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -4736.931% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -242.284% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 46.719% |
| Pluri Inc. | -20.22 Million USD | -241.167% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -757.105% |
| MeiraGTx Holdings plc | -57.05 Million USD | -20.944% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | -183.197% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -287.435% |
| CalciMedica, Inc. | -34.18 Million USD | -101.822% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 72.661% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 25.063% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -535418.736% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -99.39% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 31.827% |
| Nutriband Inc. | -5.12 Million USD | -1247.208% |
| Protara Therapeutics, Inc. | -43.27 Million USD | -59.459% |
| Compugen Ltd. | -12.51 Million USD | -451.302% |
| Roivant Sciences Ltd. | -996.51 Million USD | 93.076% |
| ProKidney Corp. | -147.66 Million USD | 53.273% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -1433.78% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -1515.819% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 38.259% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 13.225% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | -41.983% |
| Benitec Biopharma Inc. | -22.49 Million USD | -206.807% |
| GeoVax Labs, Inc. | -26.66 Million USD | -158.733% |
| Biomea Fusion, Inc. | -124.62 Million USD | 44.631% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 63.748% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 35.584% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | -201.908% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -201.354% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 71.523% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 66.8% |
| Imunon, Inc. | -19.87 Million USD | -247.118% |
| BioAtla, Inc. | -122.24 Million USD | 43.553% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 77.022% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | -66.48% |
| Zura Bio Limited | -60.56 Million USD | -13.933% |
| aTyr Pharma, Inc. | -52.17 Million USD | -32.242% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 81.84% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 70.583% |
| Galecto, Inc. | -37.51 Million USD | -83.909% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 36665.345% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 115.267% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 57.788% |
| PolyPid Ltd. | -20.26 Million USD | -240.527% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -341.946% |
| Forte Biosciences, Inc. | -32.47 Million USD | -112.461% |
| Xencor, Inc. | -125.87 Million USD | 45.182% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | -242.307% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -980.06% |
| Instil Bio, Inc. | -146.12 Million USD | 52.779% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -4409.277% |
| OncoCyte Corporation | -23.12 Million USD | -198.409% |
| Elevation Oncology, Inc. | -41.46 Million USD | -66.4% |
| Purple Biotech Ltd. | -22.22 Million USD | -210.466% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -976.459% |
| MacroGenics, Inc. | 2.01 Million USD | 3520.972% |
| Verona Pharma plc | -52.46 Million USD | -31.512% |
| Tharimmune, Inc. | -9.3 Million USD | -641.74% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 17.841% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 27.193% |
| Aditxt, Inc. | -25.45 Million USD | -171.039% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -8931.545% |
| Savara Inc. | -59.13 Million USD | -16.688% |
| Curis, Inc. | -45.13 Million USD | -52.863% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -354.218% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | -158.102% |
| BeiGene, Ltd. | -1.12 Billion USD | 93.864% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -1433.78% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -61.94% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -443.615% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | -15.286% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -306.342% |
| Adicet Bio, Inc. | -136.53 Million USD | 49.463% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -843.913% |
| Quantum-Si incorporated | -91.8 Million USD | 24.839% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Generation Bio Co. | -133.3 Million USD | 48.236% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 19.788% |
| Invivyd, Inc. | -196.61 Million USD | 64.906% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 81.558% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -643.962% |
| Moolec Science SA | -52.07 Million USD | -32.502% |
| Clearside Biomedical, Inc. | -23.05 Million USD | -199.25% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -21.579% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 1505.243% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 56.44% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 89.917% |
| Evaxion Biotech A/S | -21.4 Million USD | -222.389% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | -3.894% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 13.307% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -85.074% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | -18.209% |
| Clearmind Medicine Inc. | -8.71 Million USD | -692.144% |
| Aadi Bioscience, Inc. | -65.36 Million USD | -5.563% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 179.483% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -2726.272% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 31.565% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 54.657% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 68.85% |
| ImmunityBio, Inc. | -436.18 Million USD | 84.181% |
| Korro Bio, Inc. | -80.9 Million USD | 14.712% |
| Kineta, Inc. | -15.71 Million USD | -339.105% |
| BioVie Inc. | -31.95 Million USD | -115.964% |
| Codexis, Inc. | -49.28 Million USD | -40.01% |
| Celularity Inc. | -183.94 Million USD | 62.488% |
| Virax Biolabs Group Limited | -6.6 Million USD | -944.023% |
| Cibus, Inc. | -314.58 Million USD | 78.066% |
| Annexon, Inc. | -141.57 Million USD | 51.262% |
| Assembly Biosciences, Inc. | -64.19 Million USD | -7.485% |
| Eyenovia, Inc. | -24.1 Million USD | -186.24% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 254.075% |
| NeurAxis, Inc. | -6.66 Million USD | -935.352% |
| Regulus Therapeutics Inc. | -30.88 Million USD | -123.434% |
| Compass Therapeutics, Inc. | -48.47 Million USD | -42.349% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | -232.683% |
| Notable Labs, Ltd. | -14.4 Million USD | -379.174% |
| IN8bio, Inc. | -28.5 Million USD | -142.075% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | -257.37% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 32.36% |
| Lumos Pharma, Inc. | -36.57 Million USD | -88.682% |
| Liquidia Corporation | -70.05 Million USD | 1.499% |
| Mustang Bio, Inc. | -48.06 Million USD | -43.564% |
| Quantum-Si incorporated | -91.8 Million USD | 24.839% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 2.796% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 27.193% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | -2.304% |
| 180 Life Sciences Corp. | -22.13 Million USD | -211.742% |
| Vaxcyte, Inc. | -464.88 Million USD | 85.157% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 67.222% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -843.913% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | -141.744% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 1283.703% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -2726.272% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | -86.338% |
| PepGen Inc. | -83.58 Million USD | 17.445% |
| Moleculin Biotech, Inc. | -29.5 Million USD | -133.87% |
| Solid Biosciences Inc. | -93.43 Million USD | 26.15% |
| Palisade Bio, Inc. | -12.28 Million USD | -461.852% |
| Nutriband Inc. | -5.12 Million USD | -1247.208% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -21196.605% |
| Immuneering Corporation | -58.06 Million USD | -18.843% |
| Belite Bio, Inc | -31.52 Million USD | -118.849% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | -24.479% |
| GeoVax Labs, Inc. | -26.66 Million USD | -158.733% |
| Tourmaline Bio, Inc. | -45.37 Million USD | -52.065% |
| Altimmune, Inc. | -87.93 Million USD | 21.532% |
| Peak Bio, Inc. | -1356.23 USD | -5087606.362% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -519.343% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -333.941% |
| Neurogene Inc. | -52.28 Million USD | -31.968% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 49.446% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -721.832% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 25.82% |
| Sesen Bio, Inc. | -50.84 Million USD | -35.722% |
| argenx SE | -216.02 Million USD | 68.059% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | -141.744% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -43.233% |
| Immunome, Inc. | -28.27 Million USD | -144.07% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -302.573% |
| Design Therapeutics, Inc. | -66.32 Million USD | -4.035% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | -82.784% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 15.783% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 83.857% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 34.408% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 47.081% |
| Athira Pharma, Inc. | -116.7 Million USD | 40.875% |
| XOMA Corporation | -39.36 Million USD | -75.299% |
| Merus N.V. | -149.2 Million USD | 53.755% |
| Quince Therapeutics, Inc. | -31.26 Million USD | -120.733% |
| Rezolute, Inc. | -68.42 Million USD | -0.845% |
| Clene Inc. | -43.24 Million USD | -59.573% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -347.414% |
| BeyondSpring Inc. | -21.54 Million USD | -220.339% |
| Synlogic, Inc. | -55.16 Million USD | -25.09% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -471.059% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -548.384% |
| Peak Bio, Inc. | -1356.23 USD | -5087606.362% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | -112.54% |
| Krystal Biotech, Inc. | 17.9 Million USD | 485.394% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 41.733% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 79.786% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -1397.927% |
| MannKind Corporation | 15.12 Million USD | 556.084% |
| Ikena Oncology, Inc. | -74.39 Million USD | 7.253% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -447.931% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 439.455% |
| Gossamer Bio, Inc. | -172.15 Million USD | 59.919% |
| CohBar, Inc. | -12.06 Million USD | -471.875% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | -170.497% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -129.812% |
| Legend Biotech Corporation | -477.87 Million USD | 85.561% |
| Mural Oncology plc | -192.72 Million USD | 64.196% |
| Disc Medicine, Inc. | -91.02 Million USD | 24.196% |
| Champions Oncology, Inc. | -5.05 Million USD | -1265.275% |
| REGENXBIO Inc. | -239.46 Million USD | 71.185% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -543.775% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -23.755% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | -77.983% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 38.832% |
| Vaxart, Inc. | -74.72 Million USD | 7.658% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | -95.979% |
| Cellectis S.A. | -98.09 Million USD | 29.659% |
| Longeveron Inc. | -20.06 Million USD | -243.973% |
| Repare Therapeutics Inc. | -114.27 Million USD | 39.617% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 84.289% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 7.767% |
| Revolution Medicines, Inc. | -430.58 Million USD | 83.975% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -997.17% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | -124.109% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 7.493% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 1507.322% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -529.284% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 101.498% |
| Denali Therapeutics Inc. | -179.97 Million USD | 61.66% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -72373.952% |
| Veru Inc. | -89.97 Million USD | 23.311% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | -156.719% |
| Cingulate Inc. | -22.95 Million USD | -200.631% |
| Passage Bio, Inc. | -98.34 Million USD | 29.835% |
| Context Therapeutics Inc. | -25.06 Million USD | -175.337% |
| Exicure, Inc. | -15.53 Million USD | -344.05% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 66.515% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | -86.61% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -1057.231% |
| Nuvalent, Inc. | -149.49 Million USD | 53.843% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -748.469% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 19.667% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | -128.647% |
| OmniAb, Inc. | -49.73 Million USD | -38.748% |
| Anew Medical, Inc. | -1.3 Million USD | -5204.342% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -458.08% |
| Lipocine Inc. | -16.32 Million USD | -322.731% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | -3.496% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 7.136% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -80.947% |
| G1 Therapeutics, Inc. | -39.01 Million USD | -76.862% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | -211.054% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 87.341% |
| Ocugen, Inc. | -64.82 Million USD | -6.439% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 25.461% |
| Q32 Bio Inc. | -86.5 Million USD | 20.232% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -307.639% |
| Alumis Inc. Common Stock | -156.89 Million USD | 56.02% |
| Equillium, Inc. | -12.13 Million USD | -468.471% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | -18.007% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -773.06% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -265.84% |
| Dominari Holdings Inc. | -22.44 Million USD | -207.491% |
| Edesa Biotech, Inc. | -8.19 Million USD | -742.488% |
| vTv Therapeutics Inc. | -25.41 Million USD | -171.529% |
| Bio-Techne Corporation | 326.66 Million USD | 121.123% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 82.071% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 131.887% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 47.371% |
| Candel Therapeutics, Inc. | -37.43 Million USD | -84.342% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 54.335% |
| Nkarta, Inc. | -120.48 Million USD | 42.729% |
| BioCardia, Inc. | -11.56 Million USD | -496.894% |
| Iterum Therapeutics plc | -34.58 Million USD | -99.54% |